Catalent Announces Launch of Catalent Applied Drug Delivery Institute
News Oct 25, 2012
Catalent Pharma Solutions has announced the launch of its Catalent Applied Drug Delivery Institute at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Chicago, IL.
The Catalent Applied Drug Delivery Institute aspires to promote innovation, knowledge-sharing, and collaboration between industry leaders, academic experts, customers and regulators to enhance understanding of available, emerging, and future drug delivery technologies and improve patient care.
“The mission of the Catalent Applied Drug Delivery Institute is to bring better treatments to market by advancing the development and adoption of applied drug delivery technologies,” stated Kurt Nielsen, Ph.D., Senior Vice President of Research and Development.
“By harnessing the knowledge of some of the world’s leading experts in drug development, delivery and formulation, the Institute will cultivate leadership and excellence in drug development through education, training, and innovation.”
As part of its mission, the Catalent Applied Drug Delivery Institute will serve as a link between industry and academia by providing guidance, counsel, and resources on major issues pertaining to drug development, delivery, and formulation.
The Institute will develop programs that facilitate mutually beneficial collaborations, increase communication, and shed light on regulatory issues affecting drug developers and researchers.
It also will pursue a multi-tiered approach of seed funding, strategic counsel, and educational programs to advance the adoption of emerging technologies.
“Today is an exciting day for Catalent Pharma Solutions and the Catalent Applied Drug Delivery Institute, as well as for everyone working in the areas of drug delivery and development,” said Rao Tatapudy, Vice President of Scientific Affairs.
Tatapudy continued, “In launching the Institute at AAPS, we hope to start an informative and productive dialog between industry and academic experts that will spur innovation at the benchtop and in the marketplace. We look forward to a continuous series of successful collaborations as the Institute’s activities unfold.”
There will be a series of Institute-led initiatives designed to enhance understanding of drug delivery and inspire the next generation of science leaders. These initiatives, which will target both industry and academic audiences, will include:
• Applied Drug Delivery Events and Training Programs for Industry
• Innovation and Research Collaborations with Universities and Technology Companies
• Catalent Applied Drug Delivery Institute Scientific Journal
• Science Leaders of Tomorrow University Partnership Program
• Student Drug Delivery Guide
• Annual Drug Delivery Landscape Technology Survey
• Scientific Communications
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018